mar:val06Technology transfer

You've researched something new. Who brings it to market with you?

mar:val shows what each of your inventions is worth in its market, what a partner would need to earn with it, and names the companies — and the people in them — best placed to take it there.

Which invention first — and with whom?

Sort the same six inventions by value, by remaining term and by coverage: the most valuable is not the longest-protected, and the widest-covered sits mid-table. That disagreement is where the next transfer effort should go — and why you get all three columns rather than one figure. Pick an invention to see its market value and the partner best placed to take it there.

Technologies · inventions to market
Illustrative · anonymised

A list of six patented inventions of one research institute, sortable by value, remaining term or coverage. For the selected invention the top-down value, the annual revenue a partner would need, the remaining term, the jurisdictions covered and the best-placed partner from matchmaking are shown.

Sort by
Your inventions
Value (top-down)
$2.4M
Required revenue
$11.8M
Remaining term
13 yrs
Coverage
EPUSCNJPKR
Best-placed partner
MedTronixCorporation
What that means
Most valuable and widely covered, with a corporate partner ready to take it. The invention to bring to market first — the partner would need about five times its value in annual revenue.
Who this is for
Technology transfer officesUniversities & research institutesResearch foundations & fundersSpin-off & incubator programmesIP valuers working for academia

What you know before you approach a partner

01

A ranked list of your inventions

Value, value after tax, required revenue, remaining term, jurisdictions and technical scope — per patent family, ranked and with its share of the whole.

02

Valued without a revenue line

An institute has no product revenue to derive from, so the value is the family's top-down share of the modelled market — and the result says which derivation it used.

03

A licence fee equivalent

Per owning institution: the annual licence fee at the field's royalty rate, plus the portfolio value before and after tax. The number a negotiation can start from.

04

Partners ranked for your invention

Matchmaking ranks the companies with a reason to take your invention to market — with the strongest patent pair, semantic and category evidence per candidate, filterable to corporations or academia.

05

The people, not just the logo

The decision-makers over patent and R&D strategy at the candidate, ranked by influence, with role, source and a direct LinkedIn search.

06

The out-licensing quadrant

Every player in the field placed by technology strength against resource strength. High on technology, low on resources is the licensing zone — structurally, where an institute stands.

07

Academia kept apart from industry

Distinct institutions, families per institution, survival rate and coverage, with the academic and industrial filing curves side by side. Public-sector filers often hold the foundational art; here that is measured.

08

Evidence that this field trades

The share of active families that have changed owner, the rate of co-filed families as a proxy for partnerships, and incoming investments with their median deal size.

09

A report page written for your board

The technology transfer lifecycle spread in the PDF report: R&D per family, years to peak sales, partnership rate, annual royalty equivalent per family and five more figures, computed from your field.

Why an institute's family can be valued at all

The usual objection is that a research patent has no revenue behind it. It does not need one: the value is the licence fee a user of the technology would otherwise pay — and that is derived from the market, not from the owner.

See the data behind mar:val
  • Relief from royalty: the value is the royalty a licensee is spared, at the rate typical for the field.
  • Without an owner revenue line the value is the top-down share of the modelled market, and the combined figure says so rather than quietly falling to zero.
  • Remaining term and survival probability enter the value; age alone does not.
  • Academic ownership comes from the register's assignee type, not from guessing at the name — and co-owned families keep every owner.
  • Your institution is included regardless of size: it is set as a company of interest and passes the pipeline's minimum thresholds by design.

What you are probably asking now

Yes — top-down. The bottom-up derivation needs the owner's revenue and is zero without it, deliberately. The combined value therefore rests on the market share derivation, and the report states which of the two it used.

Know what your technology is worth.

In the demo we show you a real report from your technology field. 30 minutes, no obligation.

Questions first? kontakt@marlean.com

DEMO REQUEST

Your details stay with us. Analyses are based on public data. Privacy